Cardio Kidney Metabolic Medicine 2026: A Clinical Reference for Cardiology, Nephrology and Diabetology | SGLT2 Inhibitors, Antiobesity Therapy, Hypertension and Digital Diabetes Care: 1

Cardio Kidney Metabolic Medicine 2026 , edited by Dr. PC Manoria, presents a concise, integrated approach to the interconnected spectrum of obesity, diabetes, cardiovascular and renal disorders. It brings together evolving concepts such as novel obesity phenotypes, sarcopenic obesity and epicardial fat as biomarkers, advances in antiobesity therapy and bariatric surgery, and the emerging possibility of diabetes remission supported by continuous glucose monitoring. The book further explores contemporary challenges in hypertension management, the cardiometabolic implications of MASLD, and heart failure management in diabetes, with particular emphasis on the role of SGLT2 inhibitors, and looks ahead to artificial intelligence, digital twins and next-generation digital diabetes platforms. Who This Book Is For: Cardiologists: integrated guidance on hypertension, heart failure in diabetes, and SGLT2 inhibitor therapy across the cardio-renal-metabolic spectrum. Endocrinologists and Diabetologists: updated coverage of antiobesity medications, bariatric surgery, CGM-supported diabetes remission, and digital diabetes care. Why This Book Helps: Bridges three specialties in one reference: integrates cardiology, nephrology and endocrinology perspectives instead of leaving the reader to reconcile separate texts. Explains obesity as a cardiometabolic driver: covers phenotypes from childhood obesity to sarcopenic obesity and epicardial fat as key biomarkers. Keeps pace with rapidly evolving therapy: updated on SGLT2 inhibitors, antiobesity medications, and 2025-26 antihypertensive drugs. Looks toward technology-driven care: covers continuous glucose monitoring, AI in clinics, and digital twins for personalized management. Key Features: Integrated coverage spanning obesity, diabetes, cardiovascular and renal disease as one connected spectrum. Dedicated chapters on antiobesity medication evolution and bariatric surgery advances. CGM-supported diabetes remission and hyperkalemia roadblocks in heart failure with diabetes explained. Chapters on MASLD's link to ASCVD and 2025-26 hypertension drug updates. Forward-looking chapters on AI in clinics, digital twins and digital diabetes care platforms.

Disclaimer:

• Cardio Kidney Metabolic Medicine 2026: A Clinical Reference for Cardiology, Nephrology and Diabetology | SGLT2 Inhibitors, Antiobesity Therapy, Hypertension and Digital Diabetes Care: 1 book is not for reading online or for free download in PDF or eBook format.
• Table of Contents, Index, Syllabus, summary and image of Cardio Kidney Metabolic Medicine 2026: A Clinical Reference for Cardiology, Nephrology and Diabetology | SGLT2 Inhibitors, Antiobesity Therapy, Hypertension and Digital Diabetes Care: 1 may be of a different edition or of the same title.
• Price can change due to reprinting, price change by publisher or sourcing cost change for imported books.